Pharma faces payment disclosure law

Senator Charles Grassley said he would, and now he has: The Republican introduced a bill Thursday that would require drug and medical device makers to report almost every cent they pay to doctors. Each payment of more than $25 would have to be disclosed quarterly, and the data would be posted on a government website.

For several months now, news reports and Congressional hearings have been questioning the flow of dollars from drug makers to doctors--everything from free meals to speaking fees to consulting payments. Some doctors have reaped hundreds of thousands a year in such gifts or fees-for-services. The natural follow-up question--does it change doctors' behavior when they pick up their prescription pads?--has prompted much defensive denial, but it's also inspired fears of unnecessarily costly scrips and even patient harm.

Anticipating the outcry from pharma, Sen. Herb Kohl, the bill's co-sponsor, said that if companies have nothing to hide, then disclosure will only vindicate them. "Either way, patients win," he said.

- check out the release
- read the New York Times article

ALSO: Should drug and medical device makers be made to to report payments made to doctors? Poll

Related Articles:
Law would make pharmas reveal MD payments. Report
Psychiatrists getting largest pharma gifts. Report
NY bill would require pharmas to report MD gifts. Report
Doctors weigh in on pros, cons of accepting freebies. Letters
States tighten screws on pharma marketers. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.